Cell

Vietnam Battery Market Report 2022: Rising Focus on Technologically Advanced Batteries to Create a Massive Opportunity - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022
Energy, Other Energy, Other Manufacturing, Manufacturing, Ignition, Lithium, Kia, Motor vehicle, City, Lead, Hospital, Hyundai, SLI, Telecommunication, Solar energy, VinFast, Travel, Ford Motor Company, USD, Vingroup, CAGR, Cell, Car, Technology, LG Chem, Plant, SAMCO, Ford Vietnam, Growth, Electric battery, EV

The rising focus on technologically advanced batteries by end users and manufacturers is likely to create a massive opportunity for the battery companies to invest and redirect their resources to make a breakthrough battery technology.

Key Points: 
  • The rising focus on technologically advanced batteries by end users and manufacturers is likely to create a massive opportunity for the battery companies to invest and redirect their resources to make a breakthrough battery technology.
  • The growing demand for lithium-ion batteries in the country is expected to drive the Vietnamese battery market during the forecast period.
  • PINACO is one of the dominant players in the car battery market, accounting for nearly 40-45% of the market share.
  • The penetration of electric vehicles is anticipated to provide a massive impetus for the growth of the lithium-ion battery market.

Genetic Testing Global Market Report 2022: Featuring Key Players Abbott Laboratories, Danaher Corporation, Illumina, BioRad Laboratories & F Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022
Health, Genetics, DNA, Consciousness, Diagnosis, Investment, Awareness, Mortality, Molecular diagnostics, Research, Government, Genetics, Genetic testing, Workforce, RAD51C, Lists of diseases, Prenatal development, COVID-19, Classification, Cancer, Gene, Cell, Disease, Patient, Power, Mindfulness, Ovarian cancer, Breast, Medicine, Agriculture, Vaccine, Pharmaceutical industry, Growth

The "Genetic Testing Market Global Forecast 2021-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genetic Testing Market Global Forecast 2021-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Prominently, the global genetic testing market is driven by the increasing number of patients with genetic diseases and increasing healthcare expenditure by significant economies across the globe.
  • Besides, the growing awareness about genetic conditions, rising investments in research and development, and increasing government support further fuel the market growth.
  • For instance, molecular technology is used in genetic tests such as carrier testing, diagnostic testing, predictive & pre-symptomatic testing.

Curi Bio Launches Mantarray™ Platform – 3D Engineered Muscle Tissues for Discovery of New Therapeutics

Retrieved on: 
Wednesday, July 27, 2022
Cardiology, Stem Cells, Biotechnology, Manufacturing, Health, Pharmaceutical, Research, Genetics, Engineering, Science, Clinical Trials, Curi, Cardiomyopathy, Lists of diseases, Duchenne, EMT, Industry, Potency (pharmacology), Muscle, Tissue, Biomarker, IPSC, Drug discovery, 3D, Nautilus, Adult, Safety, Multimedia, Cell, Emergency medical technician, Duchenne muscular dystrophy, Patient, Heart, Disease, Bio, Therapy, Multi, B cell, IND, Pharmaceutical industry, Medical imaging

Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of the Mantarray platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility analysis.

Key Points: 
  • Curi Bio , a leading developer of human stem cell-based platforms for drug discovery, today announced the commercial launch of the Mantarray platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility analysis.
  • Curis Mantarray platform enables the discovery of new therapeutics by providing parallel analysis of 3D EMTs with adult human-like functional profiles of healthy and disease models.
  • View the full release here: https://www.businesswire.com/news/home/20220727005238/en/
    Curi Bio's Mantarray platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility analysis.
  • The Mantarray platform provides drug developers with clinically-relevant preclinical models that more closely recapitulate human cardiac and skeletal muscle tissues.

Empowering Tomorrow’s Great Minds in Cancer Research: The Parker Institute for Cancer Immunotherapy Awards up to $4.5 Million to Nine Early Career Researchers; Total of Over $19 Million Awarded to Date

Retrieved on: 
Wednesday, July 27, 2022
Research, Philanthropy, Continuing, General Health, University, Health, Foundation, Science, Education, Oncology, Silicon, Emma, University, Icahn School of Medicine at Mount Sinai, ESPN, Industry, Stanford University School of Medicine, Twitter, Memorial Sloan Kettering Cancer Center, Jim Valvano, CAR, Research, Parker, Institute for Systems Biology, Institute, Dana–Farber Cancer Institute, Learning, UCLA, City, Cell, Penn, Fred Hutchinson Cancer Research Center, Immunotherapy, Cancer, MSK, LinkedIn, Patient, Dana, University of California, San Francisco, Doctor of Philosophy, Washington University School of Medicine, Systems biology, Mount Sinai, Program, Informatics, MD Anderson Cancer Center, Stanford University, Mohammed V Foundation for Solidarity, Management, Pharmaceutical industry

PICI helps us further the V Foundations mission to fund accomplished young researchers bringing new techniques to combat cancer that warrant further exploration.

Key Points: 
  • PICI helps us further the V Foundations mission to fund accomplished young researchers bringing new techniques to combat cancer that warrant further exploration.
  • As part of the PICI Network, I will interact and share my ideas with some of the brightest minds in the field.
  • or Ph.D. degree and is ready to establish a laboratory or independent program in cancer immunotherapy.
  • The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done.

Berkeley Lights and Aanika BioSciences Reach Strategic Partnership Milestone By Identifying A Commercially Viable Antimicrobial Peptide

Retrieved on: 
Wednesday, July 27, 2022
Food, AMP, View, AMPS, U.S. Securities and Exchange Commission, Risk, Partnership, Health, Seed, Multimedia, Edible, Economics, Cell, Technology, Company, Nasdaq, Food safety, Peptide, Fine chemical, Mobile phone, Risk management

EMERYVILLE, Calif., July 27, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Aanika Biosciences, a growing biotech start-up using edible microbial tags to improve food safety, today announced that the companies have successfully reached their strategic partnership milestone by identifying a commercially viable antimicrobial peptide (AMP) to enable faster identification of outbreak sources, reduce incidents of fresh produce contamination and minimize the impact of food borne illness related recalls. The strategic partnership between the two companies was first announced in January 2022, and completed ahead of schedule.

Key Points: 
  • The strategic partnership between the two companies was first announced in January 2022, and completed ahead of schedule.
  • In this partnership, Aanika commissioned Berkeley Lights' high-throughput, functional screening services to rapidly identify and optimize functional AMPs capable of killing harmful bacteria to reduce contamination.
  • "We were beyond pleased to work alongside Aanika BioSciences and leverage Berkeley Lights' technology and expertise to accelerate the time to market for these AMPs," said Siddhartha Kadia, Ph.D., chief executive officer of Berkeley Lights.
  • As previously announced, Berkeley Lights will participate in the downstream economics created by its enabling technology through a royalty arrangement as part of this strategic partnership.

Noul's Hydrogel Stamping is the potential core technology necessary for precise cancer diagnosis, study confirmed

Retrieved on: 
Wednesday, July 27, 2022
Diagnosis, Time, Research, CEO, HER2, Biomarker, Tissue, Solution, Mechanics, Massachusetts General Hospital, Health, Multimedia, Cell, KOSDAQ, Philosophy, Technology, ER, Patient, Blood, Precision medicine, Life, Breast cancer, Milab, Next Generation, Harvard Medical School, Interface, AI, IHC, Medical imaging, Medical device, Typhoon Noul (2015), Multiplexing

Hydrogel Stamping identified up to nine biomarkers that diagnose breast cancer even though the amount of antibody was reduced.

Key Points: 
  • Hydrogel Stamping identified up to nine biomarkers that diagnose breast cancer even though the amount of antibody was reduced.
  • This study confirmed the potential of Hydrogel based immunostaining as a core technology necessary for precise cancer diagnosis.
  • The study hasconcluded that the developed hydrogel stamping is a highly efficient and simple immunostaining method to stain cells and tissue samples.
  • In addition, when multiple fluorescence is applied to a hydrogel used for staining, multiple analysis is possible, enabling precise diagnosis.

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Retrieved on: 
Wednesday, July 27, 2022
Optimism, Patient, Renal cell carcinoma, GLOBE, Toxicity, GBM, CD122, Sarcoma, CEO, Pancreatic cancer, Forward-looking statement, EMA, Melanoma, Bifunctional, CD25, Risk, Safety, NASDAQ, News, Immunosuppression, Cell, Journal, Immunotherapy, FDA, Company, Cancer, MDNA, Pharmacokinetics, NK, Cohort, Brain, Efficiency, Drug development, Cytokine, Pharmaceutical industry, Vaccine, Medical imaging

TORONTO and HOUSTON, July 27, 2022 (GLOBE NEWSWIRE) --  Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today announced new clinical data on safety, pharmacodynamics and anti-tumor activity from the Phase 1/2 ABILITY study of MDNA11, the Company’s long-acting IL-2 super agonist. The data, which provide preliminary evidence of MDNA11’s single agent anti-cancer activity in patients with advanced solid tumors who have been unresponsive to other treatments, are being featured in an oral presentation taking place at 1:00 PM ET today at the Cytokine Based Drug Development Summit.

Key Points: 
  • The ABILITY Studys latest data add to a body of clinical evidence we believe supports our view on MDNA11s potential as a best in class IL-2 agonist, saidDr.Fahar Merchant, President and CEO of Medicenna.
  • Merchant continued, Complementing these early anti-tumor results are pharmacodynamic data that are consistent with MDNA11s novel beta-only mechanism of action and pre-clinical evidence of tumor localization.
  • These early findings continue to fuel our optimism for the outcome of the ABILITY Study based on the evolving data as we escalate from 60 g/kg to the 90 g/ dose.
  • The ABILITY Studys dose escalation cohorts are evaluating MDNA11 monotherapy administered intravenously once every two weeks to patients with advanced solid tumors.

Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers

Retrieved on: 
Wednesday, July 27, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Antibody, Journal of Thoracic Oncology, Genetic engineering, GLOBE, Stomach, Trastuzumab, Industry, Pembrolizumab, Food, U.S. Securities and Exchange Commission, SEC, HER2, CAR, CD16, Securities Act of 1933, Securities Exchange Act of 1934, Stomach cancer, Safety, Cancer, Hackensack Meridian Health, Cell, Clinical trial, ADCC, FDA, Patient, Security (finance), Annual report, CELU, NK, Biology, Survival, Terminology, Drug Quality and Security Act, Communication, Risk, 3D ultrasound, Vaccine, Pharmaceutical industry, Instituto de Biologia Molecular e Celular

FLORHAM PARK, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that the first patient has been treated with CYNK-101, a novel allogeneic off-the-shelf human placental CD34+ stem cell derived NK cell therapeutic candidate that is genetically modified to express high-affinity and cleavage-resistant CD16 (FCGRIIIA) variant to enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Earlier this year, CYNK-101 was granted both a Fast Track Designation and an Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of human epidermal growth factor receptor 2 (HER2) positive G/GEJ cancer.

Key Points: 
  • NK cells possess inherent direct anti-solid tumor activity, recruit non-cross resistant anti-tumor T cells, and may induce memory T cells for long-term anti-cancer immune surveillance.
  • We administered 36 X 106 transduced CYNK-101/kg weekly for four weeks in combination with pembrolizumab and trastuzumab to a patient with Her2 positive gastroesophageal carcinoma.
  • Approximately 22% of patients with advanced gastric cancer have human epidermal growth factor receptor 2 (HER2) overexpression or amplification.
  • Currently CYNK-101 is being developed as a treatment in combination with standard chemotherapy, trastuzumab and pembrolizumab for HER2 positive overexpressing gastric or gastroesophageal junction adenocarcinoma.

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Retrieved on: 
Wednesday, July 27, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, GLOBE, Harvard University, Sickle cell disease, Food, Trial of the century, U.S. Securities and Exchange Commission, CEO, HBF, NCT, Forward-looking statement, CD34, Patent, Safety, CRISPR, Manifest and latent functions and dysfunctions, Cell, Clinical trial, Fetal hemoglobin, FDA, Company, Security (finance), Patient, Nasdaq, TDT, Â, SCD, Annual report, Gene editing, Mutation, Anemia, HBS, HBG1, Polymerization, Pharmaceutical industry, Vaccine, HBG2, Editas Medicine

CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the dosing and confirmed successful neutrophil and platelet engraftment of the first patient in the Phase 1/2 RUBY trial of EDIT-301 for the treatment of severe sickle cell disease (SCD). This dosing is the first time that the Company’s engineered AsCas12a enzyme, a proprietary, highly efficient, and specific gene editing nuclease, has been used to edit human cells in a clinical trial.

Key Points: 
  • It is an exciting time at Editas as we continue to build momentum for our EDIT-301 program, said Gilmore ONeill, M.B., M.M.Sc., President and CEO, Editas Medicine.
  • Sickle cell disease is an inherited blood disorder caused by a mutation in the beta-globin gene that leads to polymerization of the sickle hemoglobin protein (HbS).
  • In sickle cell disease, the red blood cells are misshapen in a sickle shape instead of the disc shape.
  • EDIT-301 is an experimental cell therapy medicine under investigation for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Retrieved on: 
Wednesday, July 27, 2022
Oncology, Health, Other Health, Other Science, General Health, Research, Science, Private Securities Litigation Reform Act, Association, Fundamental, Diagnosis, Skin, Toxicity, Stomach, Alpert Medical School, Large-cell lung carcinoma, Glioblastoma, Twitter, Dean (education), U.S. Securities and Exchange Commission, Forward-looking statement, Pancreatic cancer, Research, FACP, Alternating electric field therapy, Cancer, Mesothelioma, American Association, Adult, COVID-19, AACR, Gene, Drug resistance, Cell, Brown University, Liver cancer, Caregiver, Patient, LinkedIn, Survival, Annual report, Ovarian cancer, ONC201, American Association for Cancer Research, Population, Pharmaceutical industry, Medical imaging

Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.

Key Points: 
  • Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
  • The AACR-Novocure Grants for Tumor Treating Fields Research Program represents a joint effort between Novocure and the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields).
  • Recipients of the AACR-Novocure Tumor Treating Fields Research Grants will receive a total of $250,000 over two years.
  • Congratulations to the recipients of the AACR-Novocure Tumor Treating Fields Research Grants, said Uri Weinberg , Novocures Chief Science Officer.